Fresh off first FDA approval, Amicus spends $100M to acquire 10 gene therapies
The company acquired 10 AAV-based gene therapies in development for lysosomal storage disorders, including two already in early clinical trials.
Galafold
The company acquired 10 AAV-based gene therapies in development for lysosomal storage disorders, including two already in early clinical trials.